Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection

Zumla, Alimuddin and Atun, Rifat and Maeurer, Markus and Mwaba, Peter and Ma, Zhenkun and O'Grady, Justin and Bates, Matthew and Dheda, Keertan and Hoelscher, Michael and Grange, John (2011) Viewpoint: Scientific dogmas, paradoxes and mysteries of latent Mycobacterium tuberculosis infection. Tropical Medicine and International Health, 16 (1). pp. 79-83. ISSN 1360-2276

Documents
Zumla_et_al-2011-Tropical_Medicine_&_International_Health.pdf

Request a copy
[img] PDF
Zumla_et_al-2011-Tropical_Medicine_&_International_Health.pdf - Whole Document
Restricted to Repository staff only

63kB
Item Type:Article
Item Status:Live Archive

Abstract

Worldwide, there are nearly 10 million new cases of active TB and 1.8 million associated deaths every year. WHO estimates that one-third of the world's population is infected with Mycobacterium tuberculosis (Mtb), forming a huge latent Mtb global reservoir. This renders the prospect of ever eliminating Mtb from the human race almost impossible. Several controversial issues regarding host-pathogen interactions and existing prevention and eradication strategies for latent Mtb infections need to be critically re-examined. In this viewpoint, widely held assumptions on Mtb latency and isoniazid monotherapy and chemoprophylaxis are challenged. We highlight the need for future research to resolve these issues and to develop evidence-based strategies for better understanding of equilibrium and escape of Mtb in the human body, eventually leading to global recommendations for elimination of the latent Mtb state through informed policy and practice. Until such strategies and policies are realized, WHO and TB experts will have to settle for global TB control rather than eradication.

Keywords:Mycobacterium tuberculosi, tuberculosis, latency, isoniazid, immunology, preventive therapy, re-activation, MDR, XDR-TB, Mycobacterium tuberculosis, tuberculose, latence, isoniazide, immunologie, traitement preventif, reactivation, TB MDR, UR, latencia, isoniazida, inmunologia, terapia preventiva, reactivacion, tuberculosis multirresistente y extremadamente resistente (MDR, XDR-TB)}
Subjects:A Medicine and Dentistry > A300 Clinical Medicine
Divisions:College of Science > School of Life Sciences
ID Code:28406
Deposited On:26 Nov 2017 11:53

Repository Staff Only: item control page